These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27142176)

  • 1. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective.
    Vidal J; Slof J; Serrano D; Marqués T; Kumru H; Benito-Penalva J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):67-76. PubMed ID: 27142176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity.
    Sampson FC; Hayward A; Evans G; Morton R; Collett B
    J Neurosurg; 2002 Jun; 96(6):1052-7. PubMed ID: 12066906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy.
    de Lissovoy G; Matza LS; Green H; Werner M; Edgar T
    J Child Neurol; 2007 Jan; 22(1):49-59. PubMed ID: 17608306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.
    Postma TJ; Oenema D; Terpstra S; Bouma J; Kuipers-Upmeijer H; Staal MJ; Middel BJ
    Pharmacoeconomics; 1999 Apr; 15(4):395-404. PubMed ID: 10537958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity.
    Bensmail D; Ward AB; Wissel J; Motta F; Saltuari L; Lissens J; Cros S; Beresniak A
    Neurorehabil Neural Repair; 2009; 23(6):546-52. PubMed ID: 19228818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of intrathecal baclofen therapy in Japan.
    Hattori N; Hirayama T; Katayama Y
    Neurol Med Chir (Tokyo); 2012; 52(7):482-7. PubMed ID: 22850496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical cost impact of intrathecal baclofen therapy for severe spasticity.
    Saulino M; Guillemette S; Leier J; Hinnenthal J
    Neuromodulation; 2015 Feb; 18(2):141-9; discussion 149. PubMed ID: 25145312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intrathecal baclofen therapy and management of severe spasticity].
    Naito Y
    Brain Nerve; 2014 Sep; 66(9):1049-55. PubMed ID: 25200576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore.
    Wang ZM; Law JH; King NK; Rajeswaran DK; Soh S; Rao JP; Ng WH; Chua KS
    Singapore Med J; 2016 Jan; 57(1):8-12. PubMed ID: 26831310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.
    Albright AL; Gilmartin R; Swift D; Krach LE; Ivanhoe CB; McLaughlin JF
    J Neurosurg; 2003 Feb; 98(2):291-5. PubMed ID: 12593613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults.
    Borrini L; Bensmail D; Thiebaut JB; Hugeron C; Rech C; Jourdan C
    Arch Phys Med Rehabil; 2014 Jun; 95(6):1032-8. PubMed ID: 24407102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity.
    Sadiq SA; Wang GC
    J Neurol; 2006 May; 253(5):563-9. PubMed ID: 16328111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity.
    Berman CM; Eppinger MA; Mazzola CA
    Childs Nerv Syst; 2015 Mar; 31(3):405-13. PubMed ID: 25398671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity.
    Dan B; Motta F; Vles JS; Vloeberghs M; Becher JG; Eunson P; Gautheron V; Lütjen S; Mall V; Pascual-Pascual SI; Pauwels P; Røste GK
    Eur J Paediatr Neurol; 2010 Jan; 14(1):19-28. PubMed ID: 19541514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment.
    Mathur SN; Chu SK; McCormick Z; Chang Chien GC; Marciniak CM
    PM R; 2014 Jun; 6(6):506-513.e1. PubMed ID: 24355547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
    Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
    Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intrathecal baclofen in children and adolescents: interdisciplinary consensus table 2013.
    Berweck S; Lütjen S; Voss W; Diebold U; Mücke KH; Aisch A; Ostertag B; Friedrich M; Wagner C; Kudernatsch M; Granel M; Kluger G; Ludwikowski B; Peraud A; Rauchenzauner M; Schroeder AS; Sprinz A; Wienand R; Wilken B; Kästner S; Zeches C; Mall V;
    Neuropediatrics; 2014 Oct; 45(5):294-308. PubMed ID: 25188830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS).
    Creamer M; Cloud G; Kossmehl P; Yochelson M; Francisco GE; Ward AB; Wissel J; Zampolini M; Abouihia A; Berthuy N; Calabrese A; Loven M; Saltuari L
    J Neurol Neurosurg Psychiatry; 2018 Jun; 89(6):642-650. PubMed ID: 29326296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury.
    Stokic DS; Yablon SA; Hayes A
    Arch Phys Med Rehabil; 2005 Sep; 86(9):1801-6. PubMed ID: 16181946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.